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The purpose is to investigate prognosis according to serum CEA levels before and after sur-
gery in patients with stage IIA colon cancer who do not show high-risk features.
Methods
Among the patients diagnosed with colon adenocarcinoma between April 2011 and Decem-
ber 2017, 462 patients were confirmed as low-risk stage IIA after surgery and enrolled. The
ROC curve was used to determine cut-off values of pre- and postoperative CEA. Patients
were classified into three groups using these new cut-off values.
Results
All recurrence occurred in 52 of 463 patients (11.2%). However, recurrence in group H was
15.9%, which was slightly higher than the other two groups (P = 0.04). Group L and M
showed 10.5% and 12.8% overall survival, group H was higher at 21.0% (P = 0.005). Recur-
rence was the only risk factor in group H was significantly higher in group L (HR 2.008, 95%
CI, 1.123–3.589, P = 0.019). Mortality was similar to recurrence (HR 1.975, 95% CI 1.091–
3.523, P = 0.044).
Conclusion
Among patients with low-risk stage IIA colon cancer, recurrence and mortality rates were
higher when perioperative serum CEA levels were above a certain level. Therefore, high
CEA level should be considered a high-risk feature and adjuvant chemotherapy should be
performed.
PLOS ONE







Citation: Kim H-G, Yang SY, Han YD, Cho MS, Min
BS, Lee KY, et al. (2021) Association of
perioperative serum carcinoembryonic antigen
level and recurrence in low-risk stage IIA colon
cancer. PLoS ONE 16(6): e0252566. https://doi.
org/10.1371/journal.pone.0252566
Editor: Punita Dhawan, University of Nebraska
Medical Center, UNITED STATES
Received: November 24, 2020
Accepted: May 18, 2021
Published: June 9, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0252566
Copyright: © 2021 Kim et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting information
files.
Introduction
Colorectal cancer (CRC), the third most commonly diagnosed cancer and the second leading
cause of cancer death worldwide, has steadily increasing mortality rates; it is estimated that
>1,800,000 new cases of CRC occurred and that>860,000 people died of this disease in 2018
[1]. Surgery is the main treatment for early cases, but patients are often diagnosed in the
advanced stages and there also may be distant metastases [2]. Standard treatment of CRC with-
out metastasis (stage I-III) is radical resection of cancer lesions. Among patients with node-
positive CRC (stage III), it is common to perform postoperative adjuvant chemotherapy, and
the effect of this treatment has already been demonstrated [3].
Colon cancer and rectal cancer differ somewhat in treatment. According to the National
Comprehensive Cancer Network (NCCN) guidelines, postoperative observation is usually per-
formed when stage IIA colon cancer is not high risk and adjuvant chemotherapy is considered
an option. In rectal cancer, on the other hand, chemotherapy is the main treatment and obser-
vation is an option [4].
Carcinoembryonic antigen (CEA) is a tumor marker used to help manage colon cancer.
CEA is used to guide cancer surveillance after surgery, and high pre- and postoperative CEA
levels are as independent predictors of overall and disease-free survival [5]. The most widely
used upper margin of the normal range of CEA concentration is 5 ng/ml [6]. In early stage
colon cancer, however, CEA concentration is usually less than 5 ng/ml, which reduces diag-
nostic value. Colon cancer screening reduces mortality by identifying cancers at an earlier and
more treatable stage [7]. As screening becomes popular, early stage colon cancer is increasing.
The purpose of this study is to present a difference in recurrence according to CEA concen-
trations in patients with stage IIA colon cancer who are not at high risk. Based on these results,
we wanted to find out whether adjuvant chemotherapy could be added to a specific group.
Materials and methods
We conducted a retrospective chart review of a prospectively maintained database of all
patients who underwent curative resection of primary stage II colon cancer between January
2008 and December 2015. TNM pathologic stage II disease was diagnosed according to the
American Joint Committee on Cancer (AJCC) Cancer Staging Manual 7th edition [8].
The exclusion criteria were T4 cancer, poorly differentiated and mucinous tumor, bowel
obstruction or perforation, lympho-vascular invasion, perineural invasion, positive margins,
number of lymph nodes analyzed after surgery <12, preoperative chemotherapy or radiother-
apy, adjuvant chemotherapy, palliative resection, and lack of preoperative and postoperative
CEA data. Data on patient demographics, perioperative clinical outcomes, pathologic out-
comes, and disease status at last follow-up were collected from the database, and the electronic
medical records were reviewed.
Of the total 1,682 stage II colon cancer patients, only 463 patients were enrolled in this
study after the exclusion criteria were applied, and the data was analyzed from October 2019
to February 2020. Prior to access, all data was anonymized, and this study was approved by the
Institutional Review Board of Yonsei University Severance Hospital and the informed consent
was waived (IRB No. 4-2019-1242).
Preoperative CEA was defined as the CEA value closest to the time of surgery, and postop-
erative CEA was defined as the last CEA value within 1 month after surgery. The ROC curve
revealed that the preoperative CEA cutoff point was 3.305 ng/mL, and the calculated AUC was
0.60 (95% CI, 0.53–0.67, P = 0.009). With a CEA cut-off point of 3.305 ng/mL, the sensitivity
and specificity for predicting recurrence were 59.7% and 58.1%, respectively. The ROC curve
revealed that the postoperative CEA cut-off point was 1.86 ng/mL, and the calculated AUC
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was 0.61 (95% CI, 0.54–0.69, P = 0.003). With a CEA cut-off point of 1.86 ng/mL, the sensitiv-
ity and specificity for predicting recurrence were 54.5% and 64.0%, respectively.
Patients were grouped by CEA status as follows: (1) patients with low (<3.305 ng/mL) pre-
operative CEA and low (�1.86 ng/mL) postoperative CEA (group L); (2) patients with elevated
(�3.305 ng/mL) preoperative CEA and low (<1.86 ng/mL) postoperative CEA or patients
with low (<3.305 ng/mL) preoperative CEA and elevated (�1.86 ng/mL) postoperative CEA
(group M); and (3) patients whose preoperative and postoperative CEA levels were both ele-
vated (group H).
Statistical analyses were performed using IBM SPSS Statistics ver. 25.0 (IBM Co., Armonk,
NY, USA). To assess a cut-off value for CEA with the maximum Youden index, receiver oper-
ating characteristic (ROC) curve and area under the curve (AUC) calculations were per-
formed. Recurrence-free survival and overall survival were estimated by the Kaplan-Meier
method, and univariate analyses of the significance of prognostic factors were evaluated by the
log-rank test. Hazard ratios (HRs) and 95% CIs were estimated using Cox regression models.
A multivariate analysis of factors associated with recurrence rate was performed using the Cox
proportional hazards model with the backward stepwise (likelihood ratio) method. Variables
with P values of less than 0.1 on univariate analysis were included in the final multivariable
model. P values<0.05 were considered statistically significant.
Results
The patient demographics are shown in Table 1. The mean age was 64 years in group L, which
was slightly lower than 70.1 years in group M and 68.9 years in group H. Gender, BMI, history
of smoking, alcohol use and ASA scores were not statistically significant for each group. The
overall mean preoperative CEA concentration was 5.18 mg/dl, 1.75 mg/dl for group L,
4.63mg/dl for group M, and 10.44 mg/dl for group H. The overall mean postoperative CEA
was 2.17 mg/dl: 1.00 mg/dl for group L, 1.78 mg/dl for group M, and 4.12 mg/dl for group H.
Underlying disease was divided into six categories: hypertension, diabetes mellitus, liver
disease, lung disease, heart disease and kidney disease. Among the 463 patients, 320 patients
(69.1%) had underlying disease: 63.9% in group L, 67.9% in group M, 77.1% in group H. This
increasing trend was statistically significant with a P value of 0.007. Diabetes mellitus was
31.8% higher in group H than in groups L and M (P = 0.005). The other underlying diseases
did not show statistically significant results (Table 2).
Table 3 shows the perioperative outcomes, and although the P values were lower than 0.05,
there was no clear trend in each group. Table 4 describes postoperative outcomes. Postopera-
tive complication occurred in 24 out of 463 patients (5.2%), and there was no statistical signifi-
cance between groups. Among the pathologic outcomes of cancer, differentiation was also not
statistically significant. More than 27 lymph nodes were harvested in group L and group M,
but only 23.13 were harvested in group H, which was statistically significant (P = 0.002).
Recurrence occurred in 52 of 463 patients (11.2%). There was no significant difference
between group L (8.8%) and group M (9.0%). However, recurrence in group H was 15.9%,
which was higher than the other two groups with a p value of 0.04. Overall survival was similar
to disease-free survival: group H (21.0%) was higher than group L (10.5%) and group M
(12.8%), which was statistically significant (P = 0.005).
Disease-free survival and overall survival between groups are shown in Fig 1. In the case of
disease-free survival, group H showed statistically significantly lower results than the other two
groups (versus group L; P = 0.009, group M; P = 0.032). Overall survival was statistically signif-
icant with P value of 0.023 between group L and group H only.
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Table 1. Demographics of the patients with low risk stage IIA colorectal cancer patients.
Total (n = 463) Group L (n = 228) Group M (n = 78) Group H (n = 157) P
Age (yrs)
Mean (range) 66.7 (30–94) 64.0 (30–92) 70.1 (42–86) 68.9 (38–94) <0.001
<70 247 (53.3%) 146 (64.0%) 30 (38.5%) 71 (45.2%) <0.001
�70 216 (46.7%) 82 (36.0%) 48 (61.5%) 86 (54.8%)
Gender, n(%)
Male 272 (58.7%) 131 (57.5%) 45 (57.7%) 96 (61.1%) 0.496
Female 191 (41.3%) 97 (42.5%) 33 (42.3%) 61 (38.9%)
Body mass index (kg/m2)
Mean (range) 23.2 (13.0–41.2) 23.4 (14.4–41.2) 23.2 (15.5–29.4) 23.0 (13.0–36.9) 0.587
<25 341 (73.7%) 169 (74.1%) 57 (73.1%) 115 (73.2%) 0.861
�25 122 (26.3%) 59 (25.9%) 21 (26.9%) 42 (26.8%)
ASA score
1 142 (33.1%) 70 (30.7%) 20 (25.6%) 52 (33.1%) 0.715
2 209 (45.1%) 108 (47.4%) 38 (48.7%) 63 (40.1%)
3 103 (22.2%) 49 (20.2%) 18 (23.1%) 39 (24.8%)
4 9 (1.9%) 4 (1.8%) 2 (2.6%) 3 (1.9%)
PreCEA (mg/dl)











History of smoking 132 (28.5%) 63 (27.6%) 19 (24.4%) 50 (31.8%) 0.467
History of drinking alcohol 165 (35.6%) 83 (36.4%) 26 (33.3%) 56 (35.7%) 0.899
ASA = American Society of Anesthesiologists; preCEA: preoperative carcinoembryonic antigen; postCEA: postperative carcinoembryonic antigen
https://doi.org/10.1371/journal.pone.0252566.t001
Table 2. Underlying disease.
Total (n = 463) Group L (n = 228) Group M (n = 78) Group H (n = 157) P
Underlying disease
No 143 (30.9%) 82 (36.0%) 25 (32.1%) 36 (22.9%) 0.007
Yes 320 (69.1%) 146 (63.9%) 53 (67.9%) 121 (77.1%)
Hypertension 216 (46.7%) 97 (42.5%) 39 (50.0%) 80 (51.0%) 0.098
Diabetes mellitus 106 (22.9%) 43 (18.9%) 13 (16.7%) 50 (31.8%) 0.005
Liver disease 19 (4.1%) 10 (4.4%) 2 (2.6%) 7 (4.5%) 1.000
Lung disease 32 (6.9%) 13 (5.7%) 7 (9.0%) 12 (7.6%) 0.478
Heart disease 30 (6.5%) 15 (6.6%) 3 (3.8%) 12 (7.6%) 0.755
Kidney disease 11 (2.4%) 3 (1.3%) 1 (1.3%) 7 (4.5%) 0.061
https://doi.org/10.1371/journal.pone.0252566.t002
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Tables 5 and 6 show risk factors through a uni- and multivariate analyses of recurrence and
mortality, respectively. Recurrence rate between group L and Group H was the only risk factor
(HR 2.02, 95% CI, 1.13–3.67, P = 0.019).
Mortality was similar to recurrence. Mortality was higher in group H than in group L and
this was statistically significant (HR 1.97, 95% CI, 1.09–3.15, P = 0.041). The difference, how-
ever, is that age and gender is a risk factor for mortality. Mortality tended to be much higher in
people over 70 years of age (HR 4.44, 95% CI, 2.30–9.01, P<0.001). In addition, it was not sig-
nificant in univariate analysis, but after multivariate analysis, women showed lower mortality
than men (HR 0.46, 95% CI, 0.24–0.86, P<0.017).
Tables 7 and 8 show the results of subgroup analysis of patients with non-diabetic patients
because there were more diabetic patients in group H than other groups. In the results of
patients without diabetes, there were statistically significant differences in Groups L and H
(HR 2.25, 95% CI, 1.13–4.51, P = 0.021), and statistically significant factors were not found in
patients with diabetes.
Discussion
Carcinoembryonic antigen (CEA) is a glycoprotein with increased serum levels during cancer
progression. This is useful for diagnosing various cancers and also plays an important role in
Table 3. Perioperative outcomes.
Total (n = 463) Group L (n = 228) Group M (n = 78) Group H (n = 157) P
Tumor location
Right sided colon 217 (46.9%) 113 (49.6%) 47 (60.3%) 57 (36.3%) 0.020
Left sided colon 246 (53.1%) 115 (50.4%) 31 (39.7%) 100 (63.7%)
OP type
Right hemicolectomy 210 (45.4%) 108 (47.4%) 47 (60.3%) 55 (35.0%) 0.017
Transverse colectomy 5 (1.1%) 3 (1.3%) 0 (0%) 2 (1.3%)
Left hemicolectomy 38 (8.2%) 23 (10.1%) 5 (6.4%) 38 (8.2%)
Anterior resection 157 (33.9%) 68 (29.8%) 21 (26.9%) 68 (43.3%)
Low anterior resection 50 (10.8%) 24 (10.5%) 5 (6.4%) 21 (13.4%)
Subtotal colectomy 3 (0.6%) 2 (0.9%) 0 (0%) 1 (0.6%)
https://doi.org/10.1371/journal.pone.0252566.t003
Table 4. Postoperative outcomes.
Total (n = 463) Group L (n = 228) Group M (n = 78) Group H (n = 157) P
Postoperative Complication 24 (5.2%) 11 (4.8%) 7 (9.0%) 6 (3.8%) 0.968
Intestinal obstruction 13 (2.6%) 7 (3.1%) 3 (3.8%) 1 (0.6%)
Urinary problem 2 (0.4%) 0 (0%) 0 (0%) 1 (0.6%)
Anastomosis leakage 11 (2.2%) 2 (0.9%) 2 (2.6%) 4 (2.5%)
Bleeding 1 (0.2%) 1 (0.4%) 0 (0%) 0 (0%)
Wound infection 2 (0.4%) 0 (0%) 2 (2.6%) 0 (0%)
Intra-abdominal abscess 1 (0.2%) 1 (0.4%) 0 (0%) 0 (0%)
Differentiation
Well 51 (11.0%) 27 (11.8%) 11 (14.1%) 13 (8.3%) 0.324
Moderate 412 (89.0%) 201 (88.2%) 67 (85.9%) 144 (91.7%)
Harvested lymph nodes (n)
Mean (range) 25.92(12–113) 27.15(12–81) 27.95(12–113) 23.13(12–72) 0.002
Recurrence 52 (11.2%) 20 (8.8%) 7 (9.0%) 25 (15.9%) 0.040
Expired 67 (14.5%) 24 (10.5%) 10 (12.8%) 33 (21.0%) 0.005
https://doi.org/10.1371/journal.pone.0252566.t004
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Fig 1. Disease-free survival and overall survival between groups.
https://doi.org/10.1371/journal.pone.0252566.g001
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predicting recurrence surgical/medical treatment of cancer [9]. It is most relevant for colorec-
tal cancer, but can also be seen in malignant tumors of the esophagus, stomach, liver, and pan-
creas [10, 11]. CEA is most affected by the pathologic TNM stage and is high even in the
presence of lymphatic metastasis or nerve infiltration [12]. However, the low-risk stage IIA
colon cancer that is the subject of this study rarely has a high CEA levels. This is more often
less than 5 ng/dl, which is a criterion that is meaningful for efforts to begin raising serum CEA.
The question of whether CEA level in low-risk stage IIA colon cancer overlooked simply
because it is often lower than the reference value was the reason for this study.
The first purpose of this study was to analyze whether there was a relationship between
perioperative CEA ratio and recurrence or mortality through a pilot study, but no statistical
significance was found. In addition, based on the well-known CEA reference value of 5 ng/dl,
we also investigated whether preoperative and postoperative CEA levels can serve as risk
Table 5. Uni- and multivariate analysis of risk factors associated with recurrence using Cox regression model.
Factors Univariate Multivariate
P HR 95% CI P
Age (<70 vs. �70 years) 0.572
Gender (female vs. Male) 0.476
BMI (<25 vs.�25 kg/m2) 0.258
preCEA (<5 vs. �5 ng/mL) 0.239
postCEA (<5 vs.�5 ng/mL) 0.759
Group (L vs.H) 0.012 2.02 1.13–3.67 0.019




Complication 0.094 2.01 0.54–6.07 0.247
Histology (WD vs. MD) 0.941
preCEA: preoperative carcinoembryonic antigen, WD: well differentiated, MD: moderately differentiated, HR: hazard ratio, 95% CI: 95% confidence interval
https://doi.org/10.1371/journal.pone.0252566.t005
Table 6. Uni- and multivariate analysis of risk factors associated with mortality using Cox regression model.
Factors Univariate Multivariate
P HR 95% CI P
Age (<70 vs. �70 years) <0.001 4.44 2.30–9.01 <0.001
Gender (female vs. Male) 0.077 0.46 0.24–0.86 <0.017
BMI (<25 vs.�25 kg/m2) 0.620
preCEA (<5 vs. �5 ng/mL) 0.169
postCEA (<5 vs.�5 ng/mL) 0.205
Group (L vs.H) 0.005 1.97 1.09–3.15 0.041
Tumor site (Right vs. Left) 0.874




Histology (WD vs. MD) 0.131
preCEA: preoperative carcinoembryonic antigen, WD: well differentiated, MD: moderately differentiated, HR: hazard ratio, 95% CI: 95% confidence interval
https://doi.org/10.1371/journal.pone.0252566.t006
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factors for recurrence and mortality, but this did not produce statically meaningful results.
Therefore, the ROC curve was used to determine the cut-off value between each of the preop-
erative and postoperative CEA levels and recurrence. Although the AUC was low, we were
able to calculate a cut-off value of 3.305 ng/dL for preoperative CEA and 1.86 ng/dL for post-
operative CEA. To overcome the low AUC, combinations of the two cut-offs were divided into
three groups.
Our results showed that patients with higher perioperative CEA levels had a higher mean
age. This is contrary to a paper published by Yanfeng Gao et al. [12], but was similar to a paper
published by Tsuyoshi Konishi et al. [13] Smoking status in this study did not affect CEA lev-
els, unlike in other studies [14, 15].
In this study, preoperative and postoperative CEA levels were classified into three patient
groups. To achieve clearer results, groups from both extremes were included in the univariate
Table 7. Uni- and multivariate analysis of risk factors associated with recurrence using Cox regression model in patients without diabetes.
Factors Univariate Multivariate
P HR 95% CI P
Age (<70 vs. �70 years) 0.121
Gender (female vs. Male) 0.709
BMI (<25 vs.�25 kg/m2) 0.643
preCEA (<5 vs. �5 ng/mL) 0.152
postCEA (<5 vs.�5 ng/mL) 0.596
Group (L vs.H) 0.021 2.25 1.13–4.51 0.021





Histology (WD vs. MD) 0.629
preCEA: preoperative carcinoembryonic antigen, WD: well differentiated, MD: moderately differentiated, HR: hazard ratio, 95% CI: 95% confidence interval
https://doi.org/10.1371/journal.pone.0252566.t007
Table 8. Uni- and multivariate analysis of risk factors associated with recurrence using Cox regression model in patients with diabetes.
Factors Univariate Multivariate
P HR 95% CI P
Age (<70 vs. �70 years) 0.084 0.39 0.13–1.12 0.084
Gender (female vs. Male) 0.493
BMI (<25 vs.�25 kg/m2) 0.169
preCEA (<5 vs. �5 ng/mL) 0.867
postCEA (<5 vs.�5 ng/mL) 0.778
Group (L vs.H) 0.417





Histology (WD vs. MD) 0.515
preCEA: preoperative carcinoembryonic antigen, WD: well differentiated, MD: moderately differentiated, HR: hazard ratio, 95% CI: 95% confidence interval
https://doi.org/10.1371/journal.pone.0252566.t008
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and multivariate analyses to identify risk factors for recurrence and mortality. As a result, both
recurrence and mortality showed significant results in group H compared with group L. As
shown in Fig 1 on the extended line, comparing the Kaplan Meyer curve to determine disease-
free survival and overall survival by group, group H shows a significant result compared with
group L.
Using the univariate and multivariate models to identify risk factors for recurrence and
mortality, both showed statistically significant results for group H compared with group L. In
addition to mortality, age and risk factors also produced meaningful results, which is a natural
result because the study included many elderly patients.
When designing this study, we thoroughly screened patients with stage llA colon cancer
and excluded rectal cancer. According to the colon cancer part of the National Comprehensive
Cancer Network guideline, if the pathologic stage is T3, N0, M0 and there are no high-risk fea-
tures, the first choice of adjuvant treatment is observation, which is often used in clinical prac-
tice [4]. High-risk factors are defined as poorly differentiated / undifferentiated histology,
lymphatic/vascular invasion, bowel obstruction, <12 lymph nodes examined, perineural inva-
sion, localized perforation, or positive margins. For this reason, all patients with high-risk fac-
tors were excluded.
Adjuvant chemotherapy is known as the standard for stage III colon adenocarcinoma after
resection. The addition of chemotherapy after surgical resection of stage III colon cancer pro-
vides a 22% to 32% advantage of overall survival (OS) and a 30% reduction in the relative risk
of disease recurrence [16, 17]. Focusing on the obvious advantages of adjuvant chemotherapy
in patients with stage III colon cancer, efforts were made to similarly treat patients with stage
II colon cancer. As a result, it helps to lower survival and recurrence rates by identifying high-
risk groups that can benefit from adjuvant treatment. However, current guidance does not
support the use of CEA as an indicator for adjuvant chemotherapy [4, 18, 19]. However, there
are several opinions on the relationship between postoperative CEA and prognosis. Several
studies [20–22] have shown that postoperative CEA elevation is associated with prognosis in
patients with stage II colon cancer, while another study [23] suggests that postoperative CEA
levels in stage II disease do not affect disease-free survival. We also found no connection
between postoperative CEA level and disease-free and overall survival.
We compared the serum levels of preoperative and postoperative CEA in this study to cre-
ate groups for comparison. We confirmed that recurrence and overall survival were statisti-
cally significantly different between group H and group L based on the arbitrarily proposed
cut-off value, although it was lower than the CEA reference value. The potential benefit of
adjuvant chemotherapy in non-high-risk stage IIA colon cancer patients has not been fully
evaluated. However, since the prognosis was confirmed to be poor in patients above the refer-
ence point suggested in this study, adjuvant chemotherapy should be considered for high-risk
groups.
This analysis inevitably has the limitations and bias inherent in observational retrospective
studies. For example, there is a difference in age between each group, which may be problem-
atic because several studies report that there is a correlation between age and serum CEA level.
The timing of preoperative and postoperative CEA measurement was not controlled. Although
preoperative CEA was performed within 2 weeks before surgery, postoperative CEA was per-
formed within 1 month after surgery. In most cases, the measurements of CEA level after sur-
gery were confirmed by the examination conducted immediately before discharge, but when
discharge was early, the results of the examination performed at the first outpatient follow-up
were used. In addition, we have not controlled for other factors that can lead to false-positive
elevated CEA levels, such as liver disease, gastritis, peptic ulcer disease, chronic obstructive
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pulmonary disease, diverticulitis, and diabetes [13, 24]. In particular, diabetes was different in
each group in this study, but it was not sufficiently controlled.
Conclusions
Serum CEA level should be used as a predictor of recurrence or mortality after surgery in
patients with low-risk stage IIA colon cancer. This study suggests that the recurrence rate and
mortality rate are significantly higher when the preoperative CEA level is higher than 3.305
ng/dL and the postoperative CEA is higher than 1.86 ng/dL among patients with stage IIA
colon cancer without high-risk features. Therefore, it is necessary to classify elevated CEA level
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